{"entity":{"id":"idea-reg-two-day-cart-rapid-release","kind":"idea","name":"Two-day CAR-T manufacture paired with rapid release tests that regulators accept","aka":[],"tldr":"CAR-T can now be made in a day or two, but the safety tests to release it still take two weeks. Faster tests would let patients be treated within days.","summary":"Non-expanded or minimally expanded CAR-T processes (Novartis T-Charge and rapcabtagene autoleucel, several academic protocols) produce a product in 24-48 hours, but release still waits for compendial 14-day sterility, mycoplasma and vector copy number assays. The proposal is a regulatory pathway for rapid release: validated rapid microbial methods (PCR- or growth-based, 24-72 hours), qPCR mycoplasma, flow-based potency surrogates, and 'release-then-confirm' with infusion permitted after rapid tests and compendial tests completed in parallel, as is already accepted for some cord blood and radiopharmaceutical products.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)","url":"https://doi.org/10.1001/jamaoncol.2018.0977"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["car-t"],"targets":[],"drugs":[],"companies":["novartis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-manufacturing-cell-therapy"],"keyPapers":["paper-hernandez-jama-oncol"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Rapid release cuts vein-to-vein time for fast-manufactured CAR-T to under seven days and reduces the proportion of enrolled patients who die or progress before infusion by half, with no increase in infusion-related infections.","rationale":"Ten to twenty percent of patients referred for CAR-T never receive it, largely because of progression during the wait. Short manufacture also yields less differentiated, more persistent T cells. Rapid sterility methods are validated in blood banking and radiopharmacy where product shelf life forces the issue.","test":"Sponsor a regulator-endorsed validation study of rapid microbial methods against compendial methods on 500 CAR-T batches, then a prospective cohort using release-then-confirm with 30-day infection surveillance.","maturity":"early-clinical","actor":"regulator","cost":"medium","horizonYears":3},"route":"/ideas/idea-reg-two-day-cart-rapid-release/","neighbours":{"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"company":[{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"}],"bottleneck":[{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"}],"paper":[{"id":"paper-hernandez-jama-oncol","kind":"paper","name":"Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy","route":"/key-papers/paper-hernandez-jama-oncol/"}]}}